Your session is about to expire
← Back to Search
Cevostamab for Multiple Myeloma (CAMMA 2 Trial)
CAMMA 2 Trial Summary
This trial will study a new drug for people with a certain type of blood cancer who have not responded to other treatments.
CAMMA 2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCAMMA 2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CAMMA 2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have an active infection or have not been treated with IV antibiotics in the last 14 days.I have hepatitis C.My side effects from previous cancer treatments are mild or gone.I have been diagnosed with amyloidosis.I have not had CAR-T cell therapy in the last 12 weeks.I have had a solid organ transplant.I have been treated with drugs that boost the immune system.I have a positive test for EBV or CMV.I have had a brain-related condition like a stroke or epilepsy.I have had a stem cell transplant from a donor.I am fully active or can carry out light work.I have had side effects from previous immunotherapy.I have not had major surgery in the last 4 weeks.I haven't taken strong immune system medications, except for low-dose steroids, in the last 2 weeks.I have previously been treated with specific immune system-targeting cancer therapies.I have tested positive for HIV.I have tested positive for hepatitis B.I have been diagnosed with multiple myeloma according to IMWG standards.I have been diagnosed with progressive multifocal leukoencephalopathy.I have had BCMA-targeting treatment and my cancer is resistant to three types of treatments.My cancer is near vital organs and could worsen quickly.I need extra oxygen or have trouble breathing due to lung problems.I have a history of HLH or MAS.I've had BCMA-targeted therapy and my cancer is resistant to three types of treatment.I have or might have a long-term active Epstein-Barr virus infection.I haven't had cancer treatment in the last 4 weeks or within 5 half-lives of the drug.I have not received a live vaccine in the last 4 weeks and do not plan to during the study.I have heart problems that could affect my reaction to certain cancer treatments.I had a stem cell transplant using my own cells within the last 100 days.I do not have active COVID-19 symptoms or need IV antiviral treatment for it.I have had severe reactions to previous immune therapies.I haven't had any cancer except low-risk types in the last 2 years.I haven't had cancer treatments like mAb or ADC in the last 4 weeks, except for non-myeloma therapy.I have previously been treated with cevostamab or a similar drug.My cancer has worsened after my last treatment.I agree to not have unprotected sex or donate sperm for 2 months after my last dose of treatment.
- Group 1: Cohort B1: Prior BCMA CAR-T
- Group 2: Cohort A1: Prior BCMA antibody-drug conjugate (ADC) or chimeric antigen receptor T (CAR-T)
- Group 3: Cohort A2: Prior BCMA Bispecific
- Group 4: Cohort B2: Prior BCMA Bispecific
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals have signed up to participate in this research project?
"According to the sponsor's website, a total of 140 patients that meet the clinical trial's inclusion criteria are needed. The sponsor, Hoffmann-La Roche, will be running the trial out of various sites including Memorial Sloan Kettering Cancer Center in New york, New York and Tennessee Onc., PLLC - SCRI in Nashville, Tennessee."
Are new participants still being recruited for this clinical trial?
"That is correct. The information available on clinicaltrials.gov outlines that this research project, which was first publicized on 18th October 2022, is still recruiting participants. There are currently 3 recruitment sites active and the goal is to have 140 individuals enrolled in total."
Share this study with friends
Copy Link
Messenger